vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $57.3M, roughly 2.0× RHYTHM PHARMACEUTICALS, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs -83.0%, a 116.4% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 9.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
BY vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $57.3M |
| Net Profit | $37.6M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 33.4% | -83.0% |
| Revenue YoY | 9.0% | 36.9% |
| Net Profit YoY | 33.0% | -9.6% |
| EPS (diluted) | $0.83 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $57.3M | ||
| Q3 25 | $115.7M | $51.3M | ||
| Q2 25 | $110.5M | $48.5M | ||
| Q1 25 | $103.1M | $32.7M | ||
| Q4 24 | $104.7M | $41.8M | ||
| Q3 24 | $101.8M | $33.3M | ||
| Q2 24 | $99.4M | $29.1M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-47.5M | ||
| Q3 25 | $37.2M | $-52.9M | ||
| Q2 25 | $30.1M | $-46.6M | ||
| Q1 25 | $28.2M | $-49.5M | ||
| Q4 24 | $30.3M | $-43.3M | ||
| Q3 24 | $30.3M | $-43.6M | ||
| Q2 24 | $29.7M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -82.2% | ||
| Q3 25 | 43.1% | -102.6% | ||
| Q2 25 | 35.2% | -93.4% | ||
| Q1 25 | 36.4% | -143.7% | ||
| Q4 24 | 38.6% | -98.6% | ||
| Q3 24 | 39.3% | -132.0% | ||
| Q2 24 | 40.4% | -139.2% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -83.0% | ||
| Q3 25 | 32.1% | -103.1% | ||
| Q2 25 | 27.2% | -96.1% | ||
| Q1 25 | 27.4% | -151.4% | ||
| Q4 24 | 34.3% | -103.6% | ||
| Q3 24 | 29.8% | -131.2% | ||
| Q2 24 | 29.9% | -110.9% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-0.73 | ||
| Q3 25 | $0.82 | $-0.82 | ||
| Q2 25 | $0.66 | $-0.75 | ||
| Q1 25 | $0.64 | $-0.81 | ||
| Q4 24 | $0.68 | $-0.71 | ||
| Q3 24 | $0.69 | $-0.73 | ||
| Q2 24 | $0.68 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $139.1M |
| Total Assets | $9.9B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $388.9M | ||
| Q3 25 | $259.0M | $416.1M | ||
| Q2 25 | $218.3M | $291.0M | ||
| Q1 25 | $421.3M | $314.5M | ||
| Q4 24 | $563.1M | $320.6M | ||
| Q3 24 | $452.6M | $298.4M | ||
| Q2 24 | $730.5M | $319.1M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $139.1M | ||
| Q3 25 | $1.2B | $148.8M | ||
| Q2 25 | $1.2B | $-11.9M | ||
| Q1 25 | $1.1B | $18.9M | ||
| Q4 24 | $1.1B | $21.7M | ||
| Q3 24 | $1.1B | $11.2M | ||
| Q2 24 | $1.0B | $39.3M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $480.2M | ||
| Q3 25 | $9.8B | $506.9M | ||
| Q2 25 | $9.7B | $372.7M | ||
| Q1 25 | $9.6B | $386.7M | ||
| Q4 24 | $9.5B | $392.3M | ||
| Q3 24 | $9.4B | $363.6M | ||
| Q2 24 | $9.6B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-25.4M | ||
| Q3 25 | $38.3M | $-26.6M | ||
| Q2 25 | $16.3M | $-23.3M | ||
| Q1 25 | $27.1M | $-40.4M | ||
| Q4 24 | $175.2M | $-18.8M | ||
| Q3 24 | $19.8M | $-25.2M | ||
| Q2 24 | $40.1M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $171.2M | — | ||
| Q3 24 | $19.1M | — | ||
| Q2 24 | $39.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | — | ||
| Q3 25 | 32.8% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 163.5% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 39.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
